News

Sequana Medical announces grant of additional DSR® patent in United States

Ghent, Belgium – 1 February 2023 – Sequana Medical NV (Euronext…

Ariceum Therapeutics Appoints Radioligand Expert, Germo Gericke, M.D., as Chief Medical Officer

Dr. Gericke brings extensive experience in the research and…

ViCentra bolsters leadership team with the appointment of Leo Toole as Chief Financial Officer and expands European commercialization

Newly appointed CFO with significant experience in medical…

Neuraxpharm announces closing of acquisition of established products from Sanofi

Düsseldorf and Barcelona – February 1, 2023 – Neuraxpharm…

Pre-launch of MED3000 Eroxon™ ahead of H1 2023 launch

Futura Medical plc (AIM: FUM), a pharmaceutical company developing…

Destiny Pharma plc – US Center for Disease Control (CDC) and two major medical journals cite the importance of decolonization in preventing surgical site infections

Brighton, United Kingdom – 25 January 2023 – Destiny Pharma…

STORM Therapeutics Presents STC-15 Preclinical Data Supporting Treatment of Patients with AML at the AACR Acute Myeloid Leukemia and Myelodysplastic Syndrome Conference

Data demonstrates that STC-15, an oral METTL3 inhibitor,…

2022 Novo Holdings Seed Investments team Re-view/Business Update

Two successful exits – Syndesi and BioPhero Four portfolio…

Neuraxpharm completes its presence in the Benelux by opening an affiliate in Brussels to cover Belgium and Luxembourg

Belgium team to expand under Country Manager, Dr Pierre-Hervé…

NeoPhore completes extension to Series B financing to further advance discovery pipeline

Scientific milestones achieved significantly ahead of schedule Cambridge,…

Poolbeg announces strategic expansion of POLB 001 into oncology

Complements strong initial data from LPS challenge trial and…

STORM Therapeutics Expands R&D Leadership Team

Matthew Fyfe joins as Senior Vice President of Therapeutics …

Novo Holdings participates in portfolio company Amolyt Pharma’s $138 million financing

Amolyt is developing therapeutic peptides for rare endocrine…

Novo Holdings invests in proteomics technology company, Evosep

COPENHAGEN, DENMARK — Novo Holdings, a leading international…

Positive Initial Data Analysis in POLB 001 LPS Challenge Trial

Early data read out indicates a successful LPS human challenge…

We’d love to hear from you

For more information about Optimum Strategic Communications, please get in touch.

Get in touch

© Optimum Strategic Communications.